CSL Seqirus, a subsidiary of CSL Ltd. (CSL.AX), Thursday said that a real-world evidence study shows that a cell-based quadrivalent influenza vaccine has been more effective than an egg-based quadrivalent influenza vaccine over three consecutive influenza seasons in the U.S.
The study published in Open Forum Infectious Diseases, was conducted among individuals aged 4-64 years who had an acute respiratory or febrile illness and were tested for influenza in routine outpatient care.
"Cell-based technology allows us to provide an exact antigenic match to the WHO's identified strains, helping to improve vaccine effectiveness versus standard egg-based vaccines," explained Gregg Sylvester, Chief Health Officer and Head of Medical Affairs, CSL Seqirus.
Regarding egg-based quadrivalent flu vaccine, the vaccine contributor said that the vaccine undergoes adaptation during the manufacturing process, which might make it less effective.
CSL's stock is climbing 0.33 percent, to $275.39 on the ASX.
For comments and feedback contact: editorial@rttnews.com
Health News